Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday

Verrica Pharmaceuticals (NASDAQ:VRCA) will likely be issuing its quarterly earnings data after the market closes on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $1.30 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $0.61 on Monday. The firm has a market cap of $27.73 million, a PE ratio of -0.33 and a beta of 1.44. The firm’s 50-day simple moving average is $0.68 and its 200-day simple moving average is $1.14. Verrica Pharmaceuticals has a 1 year low of $0.58 and a 1 year high of $11.41.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a research note on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.50.

Institutional Investors Weigh In On Verrica Pharmaceuticals

A hedge fund recently raised its stake in Verrica Pharmaceuticals stock. Bank of America Corp DE increased its holdings in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 347.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 143,818 shares of the company’s stock after acquiring an additional 111,678 shares during the quarter. Bank of America Corp DE owned approximately 0.32% of Verrica Pharmaceuticals worth $101,000 at the end of the most recent quarter. Institutional investors own 42.45% of the company’s stock.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.